Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein (Q73502940)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein (English)

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

14 September 2024

L. W. Moreland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

S. W. Baumgartner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

M. H. Schiff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

E. A. Tindall

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

R. M. Fleischmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

A. L. Weaver

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

R. E. Ettlinger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

S. Cohen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

W. J. Koopman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

K. Mohler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

M. B. Widmer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

C. M. Blosch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

14 September 2024

language of work or name

English

0 references

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

17 July 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9219699

full work available at URL

14 September 2024

https://doi.org/10.1056/nejm199707173370301

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9219699

http://www.nejm.org/doi/pdf/10.1056/NEJM199707173370301

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The New England Journal of Medicine

14 September 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

141-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The mortality of rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Efficacy of low-dose methotrexate in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Cytokines in autoimmunity

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Matrix (Stuttgart, Germany). Supplement

14 September 2024

198

MacNaul KL

1992

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Isolation and characterization of a tumor necrosis factor binding protein from urine

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The Journal of Rheumatology

14 September 2024

1710

Westacott CI

1994

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Soluble tumor necrosis factor receptors in human inflammatory synovial fluids

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Journal of Acquired Immune Deficiency Syndromes

14 September 2024

Zangerle R

1994

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

High concentrations of soluble tumor necrosis factor receptors in ascites

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Plasma tumor necrosis factor soluble receptors in chronic renal failure

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values.

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Evidence of Participation of the Soluble Tumor Necrosis Factor Receptor I in the Host Response to Intrauterine Infection in Preterm Labor

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

14 September 2024

249A

Nam MH

1993

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The Journal of Rheumatology

14 September 2024

1849

Moreland LW

1996

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The Journal of Rheumatology

14 September 2024

789

Fries JF

1982

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

Unraveling function in the TNF ligand and receptor families

14 September 2024

1 reference

https://api.crossref.org/works/10.1056/NEJM199707173370301

14 September 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9219699%20AND%20SRC:MED&resulttype=core&format=json